Papadopoulos Stelios

Papadopoulos Stelios is listed in filings as Director at Exelixis Inc. This profile follows SEC Form 4 activity through May 29, 2026, including sale activity. Recent filings connect the profile to Exelixis Inc (EXEL), Ovid Therapeutics Inc. (OVID), and Regulus Therapeutics Inc. (RGLS). The current snapshot covers public activity from Mar 4, 2025 to May 29, 2026. Reported amounts are shown as $45.0K to $4.4M. The page organizes purchases, sales, issuer links, reported share activity, and filing evidence for review as public disclosure data.